Nasus Pharma Ltd (NSRX)
↓ Download CSV- Sector Manufacturing
- Incorporated L3
- Fiscal year ends Dec 31
In fiscal 2025, Nasus Pharma Ltd reported revenue of $1.24B. The company ran a net loss, with a net margin of -0.5%. It held $5.00M in total assets against $2.24M in total liabilities.
Key ratios (FY2025)
-0.4%
Operating margin
-0.5%
Net margin
-211.6%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $1.24B | — | — | — |
| Operating Income | -$4.90M | -$1.08M | -$1.15M | — |
| Net Income | -$5.86M | -$1.53M | -$1.05M | — |
| EPS (Diluted) | $-0.72 | $-0.22 | $-0.20 | — |
| Total Assets | $5.00M | $717.0K | — | — |
| Total Liabilities | $2.24M | $3.93M | — | — |
| Shareholders' Equity | $2.77M | -$3.21M | -$3.80M | -$2.79M |
| Cash & Equivalents | $1.24M | $284.0K | $193.0K | — |
| Operating Cash Flow | -$4.92M | -$665.0K | -$1.03M | — |
| Capital Expenditures | $14.0K | — | — | — |
| Shares Outstanding | 8.01M | 7.03M | 7.06M | — |